Pheochromocytoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AAM}} {{MAD}} | {{CMG}}; {{AE}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Pheochromocytoma is an [[adrenaline]] secreting tumor, that usually develops in the fifth decade of life. Symptoms start with [[tachycardia]], [[hypertension]], [[headache]] and [[sweating]]. Massive release of [[catecholamines]] can cause [[hyperglycemia]], [[malignant hypertension]] and [[metastasis]]. The [[prognosis]] of pheochromocytoma is generally good but metastatic pheochromocytoma has a 5-year survival rate of approximately 50% | Pheochromocytoma is an [[adrenaline]] secreting [[tumor]], that usually develops in the fifth decade of life. Symptoms start with [[tachycardia]], [[hypertension]], [[headache]] and [[sweating]]. Massive release of [[catecholamines]] can cause [[hyperglycemia]], [[malignant hypertension]] and [[metastasis]]. The [[prognosis]] of pheochromocytoma is generally good but metastatic pheochromocytoma has a 5-year survival rate of approximately 50%. | ||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
===Natural History=== | ===Natural History=== | ||
* Pheochromocytoma is the adrenaline secreting tumor, usually develop in the fifth decade of life. | * Pheochromocytoma is the [[adrenaline]] secreting [[tumor]], that usually develop in the fifth decade of life. | ||
*Fifty percent of pheochromocytomas in children are solitary intra-adrenal lesions, 25% are present bilaterally, and 25% are extra-adrenal. | *Fifty percent of pheochromocytomas in children are solitary intra-[[Adrenal gland|adrenal]] lesions, 25% are present bilaterally, and 25% are extra-[[Adrenal gland|adrenal]]. | ||
*Most catecholamine-secreting tumors are sporadic. | *Most [[catecholamine]]-secreting [[Tumor|tumors]] are sporadic. | ||
*However, 30% of patients | *However, 30% of patients get the [[tumor]] as a part of the familial disease. These [[catecholamine]]-secreting [[Tumor|tumors]] are more likely to be bilateral.<ref name="pmid28324046">{{cite journal| author=Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM et al.| title=Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. | journal=J Clin Endocrinol Metab | year= 2017 | volume= 102 | issue= 4 | pages= 1122-1132 | pmid=28324046 | doi=10.1210/jc.2016-3829 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28324046 }}</ref> | ||
Symptoms start with tachycardia, hypertension, headache, and sweating. If left untreated it | Symptoms start with [[tachycardia]], [[hypertension]], [[headache]], and [[sweating]]. If left untreated, it leads to [[hyperglycemia]] and [[Hypertensive crisis|hypertensive emergency]] that causes [[heart failure]] and[[Stroke|cerebrovascular strokes]]. If [[malignant]], It can [[metastasize]] to [[lymph nodes]], [[bones]], [[lungs]], and [[liver]]. | ||
===Complication=== | ===Complication=== | ||
* The massive release of [[catecholamines]] in pheochromocytoma can cause damage to [[myocytes]].<ref name="Goldman_327">{{Harvnb|Goldman|2011|pp=327}}</ref> This damage may be due to either a compromise of the [[coronary microcirculation]] or the direct toxic effects of catecholamines on myocytes.<ref name="Goldman_327" /> | * The massive release of [[catecholamines]] in pheochromocytoma can cause damage to [[cardiac myocytes]].<ref name="Goldman_327">{{Harvnb|Goldman|2011|pp=327}}</ref> This damage may be due to either a compromise of the [[coronary microcirculation]] or the direct toxic effects of [[catecholamines]] on [[cardiac myocytes]].<ref name="Goldman_327" /> | ||
Other complications may include: | Other complications may include: | ||
*[[Hyperglycemia]] due to | *[[Hyperglycemia]] due to opposition of [[insulin]] effect by high doses of [[adrenaline]] secreted by the [[tumor]]. | ||
*[[Malignant hypertension]] that may cause cerebrovascular accidents such as [[ | *[[Malignant hypertension]] that may cause [[Cerebrovascular event|cerebrovascular]] accidents such as: | ||
*[[Metastasis]] to [[ | **[[Intracranial hemorrhage]] | ||
**[[Acute coronary syndrome]] | |||
**[[Aortic dissection]] | |||
**[[Heart failure]] | |||
*[[Metastasis]] to: | |||
**[[Lymph node|Lymph nodes]] | |||
**[[Bones]] | |||
**[[Lung|Lungs]] | |||
**[[Liver]] | |||
===Prognosis=== | ===Prognosis=== | ||
* | * The [[prognosis]] of pheochromocytoma is good with treatment. | ||
* Approximately 10% recur after being resected. | * Approximately 10% recur after being [[Resection|resected]]. | ||
* | * Without treatment, patients with [[metastatic]] pheochromocytoma have a five-year survival rate of approximately 50%.<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_25_toc</ref> Survival rate may depend on the primary [[tumor]] site and sites of [[Metastasis|metastases]]. | ||
* Tumor burden, the location of metastases | * [[Tumor]] burden, the location of [[metastases]] and rate of progression are the main factors affecting [[prognosis]]. [[Metastasis]] to the [[brain]] and [[liver]] has a worse [[prognosis]] than other [[metastases]]. | ||
'''Post-surgical prognosis''' | |||
* | *Features leading to a good [[prognosis]] include small [[tumor]] size, short duration of surgery, [[systolic blood pressure]] less than 160 mmHg, and low levels of [[urinary]] [[catecholamines]].<ref name="pmid20336320">{{cite journal| author=Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC et al.| title=Trends in adrenalectomy: a recent national review. | journal=Surg Endosc | year= 2010 | volume= 24 | issue= 10 | pages= 2518-26 | pmid=20336320 | doi=10.1007/s00464-010-0996-z | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20336320 }}</ref> | ||
*Postoperative [[hypotension]] can be avoided by adequate fluid replacement. | |||
*Recurrence is more in patients with familial pheochromocytoma and extra-[[Adrenal gland|adrenal]] [[tumors]].<ref name="pmid11297571">{{cite journal| author=Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G| title=Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. | journal=J Clin Endocrinol Metab | year= 2001 | volume= 86 | issue= 4 | pages= 1480-6 | pmid=11297571 | doi=10.1210/jcem.86.4.7392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11297571 }}</ref> | |||
*Familial pheochromocytomas have a high [[incidence]] of bilateral disease. | |||
*Partial [[adrenalectomy]] is recommended for these patients with bilateral pheochromocytomas to prevent permanent [[glucocorticoid]] deficiency. | |||
*Complete bilateral [[adrenalectomy]] is recommended for [[Multiple endocrine neoplasia type 2|MEN2]]B patients. There is a high rate of recurrence compared to sporadic cases. Follow-up for a long duration after surgery is required. Most patients should undergo annual [[biochemical]] [[Screening (medicine)|screening]]. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Revision as of 03:13, 16 August 2017
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma natural history, complications and prognosis |
|
FDA on Pheochromocytoma natural history, complications and prognosis |
|
CDC on Pheochromocytoma natural history, complications and prognosis |
|
Pheochromocytoma natural history, complications and prognosis in the news |
|
Blogs on Pheochromocytoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Pheochromocytoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Pheochromocytoma is an adrenaline secreting tumor, that usually develops in the fifth decade of life. Symptoms start with tachycardia, hypertension, headache and sweating. Massive release of catecholamines can cause hyperglycemia, malignant hypertension and metastasis. The prognosis of pheochromocytoma is generally good but metastatic pheochromocytoma has a 5-year survival rate of approximately 50%.
Natural History, Complications and Prognosis
Natural History
- Pheochromocytoma is the adrenaline secreting tumor, that usually develop in the fifth decade of life.
- Fifty percent of pheochromocytomas in children are solitary intra-adrenal lesions, 25% are present bilaterally, and 25% are extra-adrenal.
- Most catecholamine-secreting tumors are sporadic.
- However, 30% of patients get the tumor as a part of the familial disease. These catecholamine-secreting tumors are more likely to be bilateral.[1]
Symptoms start with tachycardia, hypertension, headache, and sweating. If left untreated, it leads to hyperglycemia and hypertensive emergency that causes heart failure andcerebrovascular strokes. If malignant, It can metastasize to lymph nodes, bones, lungs, and liver.
Complication
- The massive release of catecholamines in pheochromocytoma can cause damage to cardiac myocytes.[2] This damage may be due to either a compromise of the coronary microcirculation or the direct toxic effects of catecholamines on cardiac myocytes.[2]
Other complications may include:
- Hyperglycemia due to opposition of insulin effect by high doses of adrenaline secreted by the tumor.
- Malignant hypertension that may cause cerebrovascular accidents such as:
- Metastasis to:
Prognosis
- The prognosis of pheochromocytoma is good with treatment.
- Approximately 10% recur after being resected.
- Without treatment, patients with metastatic pheochromocytoma have a five-year survival rate of approximately 50%.[3] Survival rate may depend on the primary tumor site and sites of metastases.
- Tumor burden, the location of metastases and rate of progression are the main factors affecting prognosis. Metastasis to the brain and liver has a worse prognosis than other metastases.
Post-surgical prognosis
- Features leading to a good prognosis include small tumor size, short duration of surgery, systolic blood pressure less than 160 mmHg, and low levels of urinary catecholamines.[4]
- Postoperative hypotension can be avoided by adequate fluid replacement.
- Recurrence is more in patients with familial pheochromocytoma and extra-adrenal tumors.[5]
- Familial pheochromocytomas have a high incidence of bilateral disease.
- Partial adrenalectomy is recommended for these patients with bilateral pheochromocytomas to prevent permanent glucocorticoid deficiency.
- Complete bilateral adrenalectomy is recommended for MEN2B patients. There is a high rate of recurrence compared to sporadic cases. Follow-up for a long duration after surgery is required. Most patients should undergo annual biochemical screening.
References
- ↑ Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM; et al. (2017). "Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas". J Clin Endocrinol Metab. 102 (4): 1122–1132. doi:10.1210/jc.2016-3829. PMID 28324046.
- ↑ 2.0 2.1 Goldman 2011, pp. 327
- ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_25_toc
- ↑ Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC; et al. (2010). "Trends in adrenalectomy: a recent national review". Surg Endosc. 24 (10): 2518–26. doi:10.1007/s00464-010-0996-z. PMID 20336320.
- ↑ Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G (2001). "Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center". J Clin Endocrinol Metab. 86 (4): 1480–6. doi:10.1210/jcem.86.4.7392. PMID 11297571.